Pathologic Processes D010335

Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes

Description

The abnormal mechanisms and forms involved in the dysfunctions of tissues and organs.   MeSH

Hierarchy View

Subtype Terms (65)

Acantholysis
 

Arrhythmias, Cardiac
106 drugs (78 approved, 28 experimental)

Ascites
66 drugs (36 approved, 30 experimental)

Atrial Remodeling
3 approved drugs

Azotemia
 

Cardiotoxicity
62 drugs (54 approved, 8 experimental)

Channelopathies
 

Chromosome Aberrations
34 drugs (28 approved, 6 experimental)

Death
21 drugs (11 approved, 10 experimental)

Dehydration
16 drugs (11 approved, 5 experimental)

Delayed Graft Function
21 drugs (15 approved, 6 experimental)

Disease
6 drugs (3 approved, 3 experimental)

Disease Attributes
1 experimental drug

Dysbiosis
23 drugs (8 approved, 15 experimental)

Emphysema
40 drugs (31 approved, 9 experimental)

Extravasation of Diagnostic and Therapeutic Materials
4 approved drugs

Femoracetabular Impingement
11 drugs (7 approved, 4 experimental)

Fibrosis
193 drugs (134 approved, 59 experimental)

Frailty
31 drugs (17 approved, 14 experimental)

Genomic Instability
 

Gliosis
 

Granuloma
38 drugs (29 approved, 9 experimental)

Granulomatosis, Orofacial
1 approved drug

Growth Disorders
33 drugs (16 approved, 17 experimental)

Hemolysis
12 drugs (8 approved, 4 experimental)

Hemorrhage
158 drugs (114 approved, 44 experimental)

Hyperammonemia
3 approved drugs

Hyperamylasemia
 

Hyperbilirubinemia
10 drugs (5 approved, 5 experimental)

Hyperplasia
25 drugs (18 approved, 7 experimental)

Hyperuricemia
57 drugs (19 approved, 38 experimental)

Hypovolemia
15 drugs (10 approved, 5 experimental)

Inflammation
508 drugs (242 approved, 266 experimental)

Intraoperative Complications
13 drugs (12 approved, 1 experimental)

Ischemia
63 drugs (36 approved, 27 experimental)

Leukoaraiosis
 

Leukocytosis
1 experimental drug

Lithiasis
 

Long Term Adverse Effects
2 drugs (1 approved, 1 experimental)

Malacoplakia
 

Menstruation Disturbances
31 drugs (19 approved, 12 experimental)

Metaplasia
2 approved drugs

Muscle Weakness
48 drugs (28 approved, 20 experimental)

Myotoxicity
 

Necrosis
6 drugs (4 approved, 2 experimental)

Neointima
2 approved drugs

Neoplastic Processes
2 drugs (1 approved, 1 experimental)

Nerve Degeneration
18 drugs (13 approved, 5 experimental)

Ochronosis
 

Ossification, Heterotopic
6 drugs (4 approved, 2 experimental)

Ototoxicity
14 drugs (10 approved, 4 experimental)

Pigmentation Disorders
6 approved drugs

Polydipsia
 

Postoperative Complications
213 drugs (153 approved, 60 experimental)

Protein Aggregation, Pathological
 

Respiratory Aspiration
27 drugs (25 approved, 2 experimental)

Retropneumoperitoneum
 

Sclerosis
71 drugs (50 approved, 21 experimental)

Shock
47 drugs (33 approved, 14 experimental)

Teratogenesis
 

Toxic Optic Neuropathy
1 experimental drug

Ulcer
74 drugs (44 approved, 30 experimental)

Vascular Remodeling
1 approved drug

Yang Deficiency
2 approved drugs

Yin Deficiency
2 approved drugs



Organization Involved with Phase 3 Indications (3)

Organization Involved with Other Experimental Indications (2)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.